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Autism spectrum disorder (ASD) is a spectral neurodevelopment disorder affecting approximately 1% of the population. ASD 
is characterized by impairments in reciprocal social interaction, communication deficits and restricted patterns of behavior. 
Multiple factors, including genetic/genomic, epigenetic/epigenomic and environmental, are thought to be necessary for autism 
development. Recent reviews have provided further insight into the genetic/genomic basis of ASD. It has long been suspected 
that epigenetic mechanisms, including DNA methylation, chromatin structures and long non-coding RNAs may play important 
roles in the pathology of ASD. In addition to genetic/genomic alterations and epigenetic/epigenomic influences, environmental 
exposures have been widely accepted as an important role in autism etiology, among which immune dysregulation and gastro-
intestinal microbiota are two prominent ones.  
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Autism spectrum disorder (ASD) is a group of complex 
neurodevelopmental disorders with large genetic/genomic 
components. Most recent surveys indicate that the median 
of ASD prevalence is about 1/160 (62 out of 10000). 
Among all individuals meeting criteria for autism, essential 
autism account for approximately 75% of the cases, and 
remaining are complex (syndromic) autism. The genet-
ic/genomic alterations identified thus far are highly hetero-
geneous, including: cytogenetic abnormalities (chromoso-
mal aneuploidy or structural rearrangement, generally refer 
to chromosome diseases) that can be detected by conven-
tional karyotyping (<5%); non-syndromic single gene muta-
tions including rare gene mutation (single nucleotide variant, 
SNV) and common gene variants (single nucleotide poly-
morphism, SNP), generally refer to single gene disorders 
that can be identified by sequencing (<5%), genomic copy 
number variants (CNV) and structural variation (SV), both 
generally refer to genomic disorders that can be detected by 
advanced genomic profiling, such as microarrays and 
next-generation sequencing (~10%–35%); syndromic ge-
netic/genomic variants (~10%) [1–5]. Figure 1 illustrates 
estimated detection rates of the ASD patients in each cate-
gory. None of the identified genes account for more than 
1% of the individuals with ASD, and more than 300–1,000 
genes could be associated with ASD. 
Genetic factors (genes and genomic regions that bear au-
tism causing mutations or autism risk variants), can only 
account for about 1/3 of ASD cases. There is still a large 
portion of heritability unexplainable by current genet-
ic/genomic findings. It is likely that epigenetic influence, 
environmental factors, and genetic-environment interactions 
all contribute to the pathogenesis of ASD.
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Figure 1  Genetic/genomic, epigenetic/epigenomic, and environmental contributions to autism spectrum disorder (ASD), a group of spectral neurodevel-
opment disorders. It is currently estimated that single-gene mutations only account for ~ 5% of all ASD cases with other genetic abnormalities contributing 
to additional 5%–35% of all cases.  
Over the decades, genetic/genomic research of ASD 
largely depended on family-based linkage and genome-wide 
association studies. Neither of these approaches is suitable 
for the discovery of de novo mutations effectively (i.e. iden-
tifying rare SNV, insertion/deletion (indel) and CNV). With 
the advent of unbiased genomic profiling technology, such 
as genome-wide microarray analysis and whole-exome or 
whole-genome sequencing approaches, we can now study at 
single-nucleotide resolution, the mutational processes that 
occur in humans from generation to generation and from 
cell to cell [6].  
1  Rare Copy number variants in ASD  
Numerous researchers have since used a range of microar-
ray-based technology, mainly comparative genomic hybrid-
ization (CGH), SNP genotyping (SNP) and CGH/SNP hy-
brid arrays to investigate the burden of copy-number vari-
ants in large cohorts of individuals with ASD, as compre-
hensively covered in several excellent reviews [1–5] and 
kept updated by a number of ASD websites (appendix). 
Several characteristics of CNVs in ASD identified in recent 
studies are summarized as follows. Roberts et al. used the 
105 K and 180 K oligonucleotide microarrays to analyze a 
sample of 65 ASD patients. The most common chromosome 
involved in the ASD was chromosome 15. In the study, they 
found that a significantly higher percentage of males were 
present in the ASD group [7]. Levy et al. also showed that, 
relative to males, females have greater resistance to autism 
from genetic causes, which is the gender effect of ASD [8]. 
Stobbe et al. [9] collected 23 adult patients (range 18–45 
years) with confirmed autism. CNVs were demonstrated in 
9 of 23 (39.1%) of patients, compared with 18.2% in pub-
lished pediatric cases of ASDs [10], which suggested that 
the adult ASD population is enriched for genomic imbal-
ance and rare CNVs. Girirajan et al. identified recurrent 
CNVs, including DPP10, PLCB1, TRPM1, NRXN1, FHIT, 
and HYDIN, that are enriched in autism by focusing on 
gene-disruptive events. Their study suggests that the type of 
CNV (i.e., duplication or deletion) and extent of DNA 
changes affect phenotypic manifestation of individuals with 
autism [11]. Liao et al. revealed that subjects with sex 
chromosomal aneuploidy are susceptible to neurodevelop-
mental disorders, including ASD [12]. Girirajan et al. found 
a significant increase in the number of base pairs of dupli-
cation was associated with autism [13].  
2  Rare single-gene mutations in ASD 
With the improvement of next-generation sequencing tech-
nologies, it is getting easier for researchers to estimate the 
contribution of de novo coding-sequence mutations to ASD. 
Several large-scale sequencing projects including whole 
exome sequencing (WES) have been made to identify nu-
merous rare single gene mutations and many de novo 
mutations of high impact could be mapped to highly 
interconnected protein network [14–19]. Relevant findings 
from these and other studies are summarized here. Recur-
rent disruptive mutations in six genes—CHD8, DYRK1A, 
GRIN2B, TBR1, PTEN, and TBL1XR1—may contribute to 
1% of sporadic ASDs [15]. Except these genes, few de novo 
mutations recurrently disrupt the same gene. Kong et al. 
found that de novo point mutations are overwhelmingly 
paternal in origin (4:1 bias) and positively correlated with 
paternal age, consistent with the modest increased risk for 
children of older fathers to develop ASD [17]. Gene- dis-
rupting mutations (nonsense, splice site, and frame shifts) 
are twice in affected versus unaffected children and have far 
more impacts on the individual [19]. These studies suggest 
that protein-truncating de novo SNVs contribute to the risk 
of ASD for about 10%–15% of probands [20]. The burden 
of de novo mutations affecting genes expressed in the brain 
is higher in individuals with ASD as compared with con-
trols [3].  
Sequencing analyses reveal the type and rates of 
small-scale mutations and pinpoints the responsible gene 
targets more definitively than does copy number or karyo-
typing. The common theme of variability of phenotype de-
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spite underlying shared genetic susceptibility increasingly 
suggests that high penetrant mutations associated strictly 
with ASD, and never with other conditions, may be ex-
tremely rare or nonexistent. However, the contribution of de 
novo events are underestimated for following reasons. First, 
in current studies, stringent criteria are used to eliminate 
false positives and many true positives fail to be detected as 
a consequence. Second, it would be likely to miss even a 
5% differential from de novo missense mutations, given the 
high background rate of neutral missense mutations. Third, 
due to exome capture limitations or errors in the reference 
genome, the coverage of genomic regions is incomplete. 
Fourth, mutation calls are made from only coding regions, 
and therefore, noncoding regions are missed that might af-
fect RNA expression or processing [19–21]. 
3  Candidate genes in ASD 
Because of the significant overlap between the genetic eti-
ology of ASD and other neuropsychiatric and neurodevel-
opmental disorders, more and more candidate genes are 
found in recent studies. At the same time, given the low rate 
of recurrence among genes with de novo mutations, esti-
mates of overall locus heterogeneity for ASD have yielded 
between 300 and 1000 genes that could confer increased 
ASD risk when subjected to de novo mutations [20].  
In recent studies, Lee et al. identified KCND2 as the 
causal gene for epilepsy. Interaction of KCND2 with other 
genes implicated in autism, and the role of KCND2 in syn-
aptic plasticity provides suggestive evidence of an etiologi-
cal role in autism [22]. Matsunami et al. used haplotype 
sharing and identified 39 variants in 36 genes that may con-
fer a genetic risk of developing autism [23]. Cukier et al. 
performed whole exome sequencing on 100 ASD individu-
als from 40 families with multiple distantly related affected 
individuals. They identified numerous potentially damaging, 
ASD-associated risk variants in genes previously unrelated 
to autism (SLIT3, CLCN2, PRICKLE1, AP4M1, WDR60, 
OFCC1). Additional alterations were found in previously 
reported autism candidate genes (CEP290, CSMD1, FAT1, 
and STXBP5). In this study, they found that variants oc-
curred in ASD candidate genes were 1.65 times more fre-
quently than in random genes captured by exome sequenc-
ing [24]. Shi et al. identified 59 candidate variants that may 
increase susceptibility to autism. Manual examination of 
this list identified ANK3 as the most likely candidate gene 
[25]. Xia et al. suggested TRIM33 and NRAS-CSDE1 as 
candidate genes for autism, and may provide a novel insight 
into the etiology of autism [26].  
Given that autism is a complex neurodevelopmental and 
neuropsychiatric disease, multiple contributing variants in 
the family may increase susceptibility. It is likely that stud-
ies focusing on de novo or inherited mutations can comple-
ment each other, and reveal a more comprehensive picture 
of susceptibility to ASDs. 
4  Common genetic variants in ASD 
The absence of classical Mendelian inheritance has led to 
the proposal that autism is polygenic involving many com-
mon variants, each with a small effect. A number of linkage 
studies and genome-wide association studies (GWAS) have 
been performed. Nijmeijer et al. studied 261 ADHD pro-
bands and 354 of their siblings to assess quantitative trait 
loci associated with ASD and identified a genome-wide 
significant locus on chromosome 7q11 [27]. Xia et al. used 
two Chinese cohorts for gene discovery (n=2150) and three 
data sets of European ancestry populations for replication 
analysis of top association signals. Meta-analysis identified 
three single-nucleotide polymorphisms and related haplo-
types; all were mapped to a previously reported linkage 
region (1p13.2) with autism [26]. Kovac et al. identified two 
single nucleotide polymorphisms (SNPs). Both are located 
in the noncoding regulatory regions of the superoxide dis-
mutase 1 (SOD1) gene, with a minor allele frequency in 
healthy population at approximately 5%. This suggests the 
importance of noncoding genetic variants in the regulation 
of gene expression [28]. Weiss LA et al. performed a link-
age and association mapping study using half a million ge-
nome-wide single nucleotide polymorphisms (SNPs) in a 
common set of 1,031 multiplex autism families (1,553 af-
fected offspring). They identified regions of suggestive and 
significant linkage on chromosomes 6q27 and 20p13, re-
spectively [29].  
Common variants such as SNPs contribute to ASD sus-
ceptibility, although individually they are associated with 
very small effects and are widely distributed across the ge-
nome. In the future, comprehensive assessment of the ge-
netic background of each individual might be of great im-
portance in better predicting clinical outcomes. 
5  Genetic pathways associated with ASD 
Several pathway analyses have been performed using either 
genetic/genomic or transcriptomic data to gain insight into 
the biological functions associated with ASD. Recent stud-
ies have led to a convergence on three functional pathways 
among ASD and ID (intellectual disability): (i) synaptic 
function; (ii) Wnt signaling during development; and (iii) 
chromatin remodeling [20].  
CNV studies have provided strong evidence for the in-
volvement of important gene networks in ASD. In an early 
whole-genome CNV study in 2009, Glessner et al. present-
ed the results on a cohort of 859 ASD cases and 1,409 
healthy children of European ancestry [30]. In 2010, Pinto 
et al. compared 996 ASD individuals of European ancestry 
to 1,287 matched controls to screen for rare CNVs [31]. 
Among the de novo and inherited CNVs, many novel ASD 
genes such as SHANK2, SYNGAP1, DLGAP2 and the 
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X-linked DDX53–PTCHD1 locus were implicated [31]. 
Although these variants may be individually rare, they tar-
get genes involved in synaptic formation, neuronal 
cell-adhesion or ubiquitin degradation and GTPase/Ras 
signalling, indicating that these important gene networks 
expressed within the central nervous system may contribute 
to the genetic susceptibility of ASD. Chow et al. provided 
evidence for dysregulation of pathways governing cell 
number, cortical patterning, and differentiation in young 
autistic prefrontal cortex. In contrast, adult autistic prefron-
tal cortex showed dysregulation of signaling and repair 
pathways [32]. Gilman et al. developed a method for net-
work-based analysis of genetic associations (NETBAG) to 
identify gene networks affected by rare de novo CNVs in 
ASD. Their data uncovered networks critical in synapse 
development, axon targeting, and neuron motility [14].  
Using gene expression, protein–protein interactions, and 
CNV pathway analysis, a few reports have highlighted the 
role of synapse formation and maintenance and supported a 
role for these interconnected pathways in neuronal stem cell 
fate determination, differentiation and synaptic formation in 
ASD cases and animal models [14,16,33,34]. The Wnt sig-
naling pathway plays a crucial role in diverse processes 
associated with formation of neural circuits [14].  
These pathways provide potential drug targets for ASD. 
Clinical trials are ongoing to determine whether targeting 
them could improve the symptoms of individuals affected 
by ASD. 
6  Epigenetic influences in the pathogenesis of 
ASD 
Hundreds of ASD-associated genes have been identified. 
However, a large portion of heritability remains unexplain-
able by genetic findings, including those monozygotic (MZ) 
twins who are discordant for ASD. Therefore, it has long 
been suspected that epigenetic influences may contribute to 
the pathogenesis of ASD. Epigenetic/epigenomic mecha-
nisms, including DNA methylation, chromatin remodeling 
by histone modifications (methylation, acetylation, phos-
phorylation, etc.) or ATP-dependent SWI/SNF complexes, 
may impacts on the quantity and quality of gene products at 
different levels [35,36]. Efforts have been made to elucidate 
the roles of these factors in ASD. 
6.1  Altered DNA methylation in ASD 
Altered DNA methylation has been found during brain de-
velopment in several neuropsychiatric diseases [37–40]. 
MECP2, a well-known epigenetic regulation gene, has been 
reported to be truncated or aberrantly methylated in Rett 
syndrome and autism [41,42]. Besides, ASD-associated 
genes, including OXTR [43], SHANK3 [44], FMR1 [45], 
have also been found to have hypermethylation status in 
their promoters or upstream regions among ASD patients. 
These findings support that aberrant DNA methylation may 
have an important role in ASD pathogenesis. 
To further examine the contribution of DNA methylation 
to ASD, Nguyen et al. conducted a large-scale methylation 
profiling study by using lymphoblastoid cell lines from MZ 
twins discordant for autism and unaffected siblings. They 
identified over 200 differentially methylated CpG islands, 
with an enrichment of “nervous system development and 
function” in gene ontology analysis (GO) [46]. In 2014, two 
important studies further addressed role of DNA methyla-
tion in ASD. Ladd-Acosta et al. performed a genome-wide 
screen of DNA methylation in post-mortem brain tissue 
from 19 autism cases and 21 unrelated controls [47]. They 
identified 4 genome-wide significant differentially methyl-
ated regions (DMRs) and replicated 3 of them, although no 
known ASD-associated genes showed abnormal methyla-
tion in this study. Wong et al. carried out genome-wide 
analyses of DNA methylation in 50 monozygotic twin pairs 
discordant for ASD [48]. In addition, DNA methylation was 
significantly correlated with the Childhood Autism Symp-
tom Test (CAST) scores. These two genome-wide DNA 
methylation findings in ASD have revealed numerous hy-
permethylated loci with candidate genes, but few of them 
have overlap with known ASD-associated genes identified 
from sequencing or CNV studies. This raised the question 
of the precise role of DNA methylation in ASD pathogene-
sis. Future studies are necessary for validate previous find-
ings in larger sample cohorts and examine the effect of 
these newly identified genes in ASD pathogenesis.  
6.2  Chromatin remodeling genes in ASD 
Chromatin remodeling genes contribute to the fine-tuning of 
DNA condensing status and to the regulation of open con-
formation so as to allow the accessibility of transcription 
factors. Post-translational modifications, such as methyla-
tion, acetylation and phosphorylation of histone subunits, 
can alter the chromatin structure or conformation. Chroma-
tin remodeling proteins are essential for neural development 
and dynamic activity. Alterations of these regulators can 
lead to neurological lesions [49–52]. 
Previous CNV and exome studies have revealed a num-
ber of chromatin remodeling genes harboring disruptive 
mutations in ASD patients. KDM5C encodes a histone de-
methylase. KDM5C mutations have been associated with 
X-linked mental retardation and ASD [53,54]. ARID1B, a 
component of SWI/SNF chromatin remodeling complex is 
important for speech development. ARID1B truncation mu-
tations have been identified in ASD patients [55]. CHD8, an 
ATP-dependent helicase in Wnt signaling pathway, have 
recently been recognized as a frequently mutated genes in 
ASD [15,16,56,57]. Interestingly, the expression of SCN2A, 
another ASD- associated gene which also shows a high oc-
currence in ASD exome findings [18,58], is under the regu-
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lation of KDM5C [59]. Recently, an integrative analysis of 
several published exome studies in ASD showed an 
over-representation of changes in chromatin regulatory 
genes in ASD cases as compared with unaffected siblings 
[60]. These results suggest an important role of chromatin 
remodeling genes in ASD pathogenesis. 
7  Long non-coding RNAs (lncRNAs) in ASD 
Long non-coding RNAs can modulate chromatin structure 
and conformation by their association with regulatory pro-
teins [61,62]. In a lncRNAs transcriptome study of 
post-mortem brain tissue of ASD patients [63], 222 differ-
entially expressed lncRNAs between ASD and controls 
were identified, with an enrichment of genes associated 
with neuronal migration. It should be cautioned that the 
sample size was small with only 2 patient samples with 2 
controls in this study.  
8  Environmental factors in the pathogenesis of 
ASD 
Environmental exposures have been proposed to contribute 
to ASD pathogenesis, among which immune responses and 
gastrointestinal microbiota are the two prominent ones. Ac-
cumulating evidence supports that these environmental fac-
tors may modulate known ASD candidate genes. 
8.1  Immune dysregulation in ASD 
Immune proteins play crucial roles in brain development 
[64]. The MHC-I (major histocompatibility complex class I) 
proteins, a key player in adaptive immunity, is enriched in 
synaptic fractions and the deficiency of which can result in 
enlarged neural projections [65]. MHC-I can negatively 
regulate synapse density during the formation of cortical 
connections via signaling pathways which require MEF2, an 
ASD candidate gene [66,67]. C1q and C3 (complement 
proteins of the innate immune system), and TNF-α are all 
expressed in the developing brain and play vital roles in 
synapse refinement [68,69]. Although there is no definitive 
conclusion that immune dysfunction can cause neurodevel-
opmental disorders such as ASD, maternal immune activa-
tion and increased levels of pro-inflammatory cytokines in 
the fetal brain may affect fetal brain development if the time 
of exposure coincides with critical processes in neurode-
velopment, such as dendritic pruning and synaptic scaling 
[68,70]. 
Maternal immune activation during the first or second 
trimesters has been recognized as a potential risk factor for 
ASD in the offsprings [71,72]. Anti-fetal antibodies can 
pass the blood-brain barrier which is not fully developed 
during the prenatal period [73]. Braunschweig et al. identi-
fied that anti-fetal brain antibodies, IgG, were found in 
~11.5% of mothers of children with ASD, but not in moth-
ers of children of typical development and mothers of chil-
dren with development delay [74]. Injections of IgG col-
lected from mothers of children with ASD into pregnant 
rhesus monkeys during the first and second trimesters led to 
altered brain volume and social behavior development in the 
offspring [75]. Analyses of post-mortem brain tissues of 
ASD patients with ages ranging from children to adults 
have revealed microglia activation and increased cytokines 
including TNF-α and IL-6, suggesting ongoing neuroin-
flammation in the brains of ASD patients [76,77]. These 
findings indicate that immune responses may impact on 
ASD pathogenesis. 
Microglial cells, the “immune cells in brain”, have vari-
ous functions in the central nervous system. They can se-
crete TNF-α and IL-6 under inflammatory conditions, pro-
vide growth factors in early synaptogenesis, eliminate re-
dundant synapses, and modulate synaptic transmission 
[78,79]. Morgan et al. found microglial cells were activated 
in approximately 40% of their autism samples together with 
an increase in the average microglial somal volume in white 
mater [77]. Suzuki et al. further investigated the patterns of 
distribution of microglial activation in the brain of ASD 
patients by PET imaging, and found increased microglial 
activation in the dorsolateral prefrontal cortex in ASD pa-
tients although the microglial distribution patterns were 
similar [80]. 
Immune response is not specific for autism and is espe-
cially critical in crucial fetal development stage, which 
suggests genetic factors may act as a modifier in its impact 
on brain development. Since TSC-mTOR signaling is a 
known modulator of immune response, Ehninger et al. in-
vestigated the effect of the cooperation of TSC2 haploinsuf-
ficiency with gestational immune activation and found it 
can perturb social behavior in adult mice [81]. Moreover, 
transcriptome analyses have provided convergent evidence 
supporting the role of immune genes in ASD. Voineagu et 
al. examined gene expression profiling of prefrontal and 
temporal cortex of post-mortem brain tissues of ASD pa-
tients from different age groups and through a net-
work-based approach identified two central modules of 
co-expressed genes which were dysregulated in ASD pa-
tients. One of these modules was upregulated and enriched 
for genes involved in immune and inflammatory responses 
[34]. Further genetic and functional studies will improve 
our understanding of the involvement of immune responses 
in ASD. 
8.2  Gastrointestinal microbiota in ASD 
Immune responses may also cause gastrointestinal (GI) 
problems through inflammation as well [82]. Various stud-
ies have reported the prevalence of GI problems, one of 
common comorbid conditions of ASD [83,84]. Accumulat-
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ed findings lead to the hypothesis of gut-brain axis, which 
suggests that gut microbiota can alter brain activity through 
endocrinal, metabolic or immunological mechanisms, and 
can possibly induce the pathogenesis of ASD [85–88].  
Gut microbiota may influence the development of social 
behavior. It was reported that germ-free (GF) mice showed 
significant social behavior impairments, particular in males, 
and that microbial interventions could ameliorate the social 
avoidance in GF mice without affecting social cognition 
impairments [89]. In 2013, Hsiao et al. did a remarkable 
study in which they found mice offspring affected by ma-
ternal immune activation, which display defects in intestinal 
integrity and ASD-like behavioral abnormalities, can have 
its intestinal and behavioral symptoms both ameliorated 
after receiving the treatment after weaning with the gut 
bacterium Bacteroides fragilis [90]. This is the first report 
that altered behavioral abnormalities can be alleviated by 
restoration of GI microbiota, which strongly supports the 
gut-brain axis hypothesis.  
So far most studies on the relationship between GI prob-
lems and ASD are mainly conducted in rodent or primate 
models generated by maternal immune activation, while 
studies using human samples have no reports of the diag-
nosed genetic basis, this leads to the question of whether GI 
problems only exist in subgroups of offspring of maternal 
immune activation and whether probiotic treatment for ASD 
children with single-gene mutation or CNV can also im-
prove their conditions. Besides, it is also interesting that 
whether probiotic treatment at different postnatal stage may 
have impacts of different levels on brain development of 
ASD children, since currently no studies in this sub-area 
involves the critical period of children development. These 
warrant deeper collaboration between medical geneticists 
and clinician, and further study of the mechanism through 
which gut microbiota can alter the activity of brain. 
9  Valuable ASD websites and resources  
9.1  AutDB  
AutDB (http://autism.mindspec.org/autdb/Welcome.do )  
(Appendix 1), cataloguing a richly annotated gene list for  
autism and maintained by MindSpec, has the manually cu-
rated information of different types of research data from 
association studies, chromosomal structural variation stud-
ies, studies of genetic disorders with single-gene mutations, 
and animal model studies, etc. Experts in different special-
ized fields are hired to extract information from published 
papers on autism to keep AutDB with latest up-to-date in-
formation. Listed genes are categorized as “Genetic Associ-
ation”, “Syndromic”, “Functional” and “Rare single gene 
variant”. In the section of each gene, a basic summary and 
corresponding references are provided alongside with the 
information of both rare and common sequence variants, 
animal model existence, and protein interactions. In “Ani-
mal Model” part, construct details and phenotypic profile is 
available, while in “PIN” (protein interaction) part, all 
known linked genes are presented as a colored diagram and 
a detailed table as well. AutDB also contains a section of 
listed information of CNV research in autism and imple-
ments a helpful search query engine based on researchers’ 
interests. 
9.2  SFARI gene  
Simons Foundation received the licensed AutDB from 
MindSpec in 2008, and the licensed AutDB is thus named 
as SFARI Gene (https://gene.sfari.org/autdb/Welcome.do) 
(Appendix 2). SFARI adds an additional interactive module 
which enables research community to contribute their an-
notations to genes. This module implements a process for 
gene scoring and classifies genes based on their relevance to 
autism into six categories of confidence level from “Highly 
Confidence” to “Not Supported”, and an another category 
of “Syndromic”. This module encourages the participation 
of community researchers, and the gene score is quite intui-
tive for further consideration of functional studies or bioin-
formatic analysis. Besides this major difference, SFARI 
also adds other additional information. For example, in 
“Animal Models” section, a “Rescue Models” information 
is provided which mainly contains pharmaceutical interven-
tion which helps to alleviate autism phenotypes, thus help-
ing researchers further examine the function of these genes 
in the context of development. 
9.3  Autism chromosome rearrangement database  
Autism chromosome rearrangement database (http://projects. 
tcag.ca/autism/) (Appendix 3), hosted by The Centre for 
Applied Genomics (TCAG) of the Hospital for Sick Chil-
dren, Toronto, is a database listing curated structural vari-
ants finding in autism spectrum disorder. This database 
contains not only extracted information from published lit-
erature but also in-house experimental data. It implements 
three types of information retrieval: the “Cytogenetic Data” 
centralized, the “Microarray Data” centralized, and the 
“Keyword Search” method which allows user to search for 
matched data of clone name, accession number, cytoband or 
gene symbol. The description information of individuals is 
provided but not in the form of tabularized data as in the 
case of AutDB and SFARI. 
9.4  DECIPHER  
DECIPHER (http://decipher.sanger.ac.uk/) (Appendix 4) 
(Database of Chromosomal Imbalance and Phenotype in 
Humans Using Ensemble Resources), maintained by Wel-
come Trust Sanger Institute, is an interactive database and 
has a suite of tools for researchers to interpreter chromoso-
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mal structural variations. It contains chromosomal aberra-
tions upload by more than 200 centers comprising more 
than 10,000 cases which are found not only in autism but in 
other developmental disorders as well. Users can view re-
lated information based on syndromes or karyotypes. The 
interface shows recorded copy number changes in color 
(“Loss” in red, and “Gain” in blue), while genes of recog-
nized clinical importance are highlighted. The pathogenic 
contribution of the variants can be further viewed either in 
UCSC genome browser or Ensemble browser in which the 
genomic and phenotypic information of each patient har-
boring the variants can be retrieved. The graphical presenta-
tion greatly enhances to assess clinical relevance of copy 
number change in users’ data intuitively. 
9.5  AutismKB  
AutismKB (http://autismkb.cbi.pku.edu.cn/index.php) (Ap-
pendix 5), hosted by Peking University, is an evi-
dence-based knowledgebase for ASD. It currently contains 
3075 genes, 4964 copy number variations and 158 linkage 
regions associated with ASD based on the met of following 
criteria: genome-wide association studies, genome-wide 
CNV studies, linkage analysis, low-scale genetic association 
studies, expression profiling and other low-scale gene stud-
ies, and these information can be browsed in the section of 
corresponding research method. Although the total numbers 
apparently are over-estimated and the criteria are quite loose, 
this database provides a “high-confidence” list of 99 syn-
dromic autism related genes and 109 non-syndromic autism 
associated genes based on its scoring and ranking system. 
AutismKB also enables users to view the result of gene set 
enrichment analyses by enriched GO, enriched pathway or 
enriched GO map, providing information in the context of 
gene ontology. 
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